A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded a decrease of -16.58%. However, over the last six months, the performance has been stronger by -27.92%. The price of KYMR increased 5.47% over the last 30 days. And in the last five days, it has surged by 34.13%.
In terms of market performance, Kymera Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $53.27 on 09/26/24, and the lowest value was recorded at $19.44 on 04/09/25.
52-week price history of KYMR Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Kymera Therapeutics Inc’s current trading price is -37.00% away from its 52-week high, while its distance from the 52-week low is 72.59%. The stock’s price range during this period has varied between$19.44 and $53.27. The Kymera Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.3 million for the day, a figure considerably higher than their average daily volume of 0.7 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Kymera Therapeutics Inc (KYMR) has experienced a quarterly decline of -24.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.18B and boasts a workforce of 188 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 36.11, with a change in price of -12.42. Similarly, Kymera Therapeutics Inc recorded 624,190 in trading volume during the last 100 days, posting a change of -27.01%.
KYMR’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for KYMR stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.09.
KYMR Stock Stochastic Average
As of today, Kymera Therapeutics Inc’s raw stochastic average for the last 50 days stands at 72.56%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 98.33%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 84.35% and 67.82%, respectively.
